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Abstract
Pyruvate kinase (PKLR) is a critical erythrocyte enzyme that is required for glycolysis and
production of ATP. We have shown that Pklr deficiency in mice reduces the severity
(reduced parasitemia, increased survival) of blood stage malaria induced by infection with
Plasmodium chabaudi AS. Likewise, studies in human erythrocytes infected ex vivo with P.
falciparum show that presence of host PK-deficiency alleles reduces infection phenotypes.
We have characterized the genetic diversity of the PKLR gene, including haplotype struc-
ture and presence of rare coding variants in two populations from malaria endemic areas of
Thailand and Senegal. We investigated the effect of PKLR genotypes on rich longitudinal
datasets including haematological and malaria-associated phenotypes. A coding and possi-
bly damaging variant (R41Q) was identified in the Thai population with a minor allele fre-
quency of ~4.7%. Arginine 41 (R41) is highly conserved in the pyruvate kinase family and
its substitution to Glutamine (R41Q) affects protein stability. Heterozygosity for R41Q is
shown to be associated with a significant reduction in the number of attacks with Plasmo-
dium falciparum, while correlating with an increased number of Plasmodium vivax infec-
tions. These results strongly suggest that PKLR protein variants may affect the frequency,
and the intensity of malaria episodes induced by different Plasmodium parasites in humans
living in areas of endemic malaria.
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Introduction
Malaria is one of the clearest examples of host genetic contributions to susceptibility to infec-
tions (reviewed in [1–4]). Indeed, the number of clinical episodes of malaria, the level of blood
parasitemia during infection, the rate of transmission (gametogenesis), and the severity of dis-
ease developed (mild, severe malaria-induced anemia, cerebral malaria), all show a strong heri-
table component [1, 2, 5–10]. The complexity and nature of the genetic factors regulating these
traits have been studied in case-control studies with candidate genes and in a few family-based
genome wide linkage analyses [1, 2, 11–14]. Genetic variants affecting invasion of erythrocytes
by merozoites, intra-erythrocytic replication or elimination of parasitized RBC have a major
effect on infection. For example, the Duffy antigen is the receptor for P. vivax on erythrocytes
and its absence in the Duffy negative blood group prevents parasite entry in erythrocytes and
protects against P. vivaxmalaria [12, 13]. Glycophorins (GYPA, GYPB, GYPC) bind to Plas-
modium surface proteins, and GYPC-non expressing individuals show reduced invasion of
erythrocytes, and are protected from infection [14]. Deletion of the anion exchanger Band 3
protein causes Melanesian ovalocytosis, which is also linked to reduced malaria incidence [15].
Heterozygosity for mutant haemoglobin (Hb) variants causing either sickle cell anemia (HbS)
[16, 17] or thalassemias [4, 18–20] provide significant protection against malaria, with strong
positive selection of mutant alleles in malaria-endemic areas. Glucose-6-phosphate dehydroge-
nase (G6PD) is required for glutathione production and protection against Hb degradation-
induced oxidative stress damage. G6PD deficiency offers very strong protection against P.
vivax but not against P. falciparummalaria [11]. Finally, A/B blood group antigens contribute
to rosetting of parasitized RBCs, and a recent large population study has identified diminished
risk of malaria in the O blood group [21, 22].
Pyruvate kinase (PK) catalyzes the last rate-limiting step of glycolysis. There are two genes
in humans that code for pyruvate kinases, the liver/erythrocyte-specific enzyme (PKLR) and
the muscle specific enzyme (PKM1/2). In mature erythrocytes, PKLR is essential for energy
generation [23]. PKLR is active as a tetramer, removing the phosphate from phosphoenolpyr-
uvate (PEP), and producing pyruvate and ATP [23–27]. PK-deficiency (OMIM#266200) is the
most common cause of non-spherocytic hemolytic anemia, and is inherited in an autosomal
recessive manner [24, 28, 29]. Clinical manifestation of PK-deficiency in humans ranges from
mild compensated hemolytic anemia to severe hemolysis causing neonatal death [23, 24, 29–
31]. In mice, Pklr-deficient strains AcB55 and AcB61 (PklrI90N) and CBA/Pkslc (PklrG338D) dis-
play haemolytic anemia caused by homozygosity for loss of function mutations in the Pklr
enzyme. Following infection with P. chabaudi AS, these Pklr-deficient mice show decreased
peak parasitemia and decreased mortality [31, 32]. On the other hand, we have previously
shown that erythrocytes from PKLR-deficient human patients are significantly less permissive
to P. falciparum infection than PKLR-sufficient erythrocytes [30]. In addition, erythrocytes
from heterozygous PKLR-deficient patients parasitized with P. falciparum are phagocytised at
appreciably greater levels than control parasitized erythrocytes [30, 33]. Therefore, PKLR-defi-
ciency in humans is associated ex vivo with reduced erythrocyte invasion and increased phago-
cytosis of early-stage infected erythrocytes.
Sequencing the PKLR gene from 387 normal individuals from different regions of the world
including areas where malaria is endemic (CEPH Human Diversity Panel) showed that the
Sub-Sahara African cohort exhibited the highest genetic diversity within PKLR, while the Euro-
pean population exhibited the lowest level of genetic diversity [34]. These findings were repli-
cated in another study, suggesting that the PKLR gene has been under selective pressure,
possibly due to malaria [35]. On the other hand, case-control studies have not detected associa-
tion of PKLR variants with malarial phenotypes [35, 36]. However, disease-based cohorts with
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single clinical end-points (presence or absence of disease) are not optimal to test the potential
protective effects of PKLR variants on human malaria. In such cohorts, it is difficult to distin-
guish individuals with ‘temporal’ resistance (non-infected, infected but asymptomatic, or dis-
playing sub-clinical phenotypes at the time of sampling) from those with true resistance,
whereby these individuals are infected but do not develop disease (severe or otherwise) [8].
These issues can be best addressed in longitudinal studies of community-based cohorts,
wherein different quantitative malarial phenotypes such as fever, parasitemia, type and number
of malaria episodes are studied over time in the same individuals. Genetic studies in these
unique cohorts have increased sensitivity and can detect genetic effects on different discrete
disease endophenotypes [8, 37, 38]. In this study, we took advantage of two longitudinal popu-
lation studies conducted in the malaria endemic areas of Senegal and Thailand, to identify
whether PKLR gene variants are associated with protection against the incidence or severity of
malarial infections.
Materials and Methods
Population Studies
The population cohorts and associated longitudinal population studies in the Senegalese vil-
lages of Dielmo and Ndiop (n = 878) [7, 8, 39] and the studied Thai population (n = 897) [6, 7,
11] have been previously described. Passive and active surveillance for identification of clinical
and subclinical phenotypes has been described [6–8, 11, 39–41]. Human DNA samples were
obtained with written informed consent, and were approved by the ethical review Committee
for Research in Human Subjects, Ministry of Public Health, Thailand. In Senegal, the project
was approved by the Ministry of Health of Senegal, and by the village population. Approval is
renewed on a yearly basis. Written informed consent was obtained from all participants over
the age of 15 years or from the guardians of children younger than 15 year. In all cases, such
consent was obtained in the presence of the school director, an independent witness. Written
consent was recorded on a voluntary consent form written in both French and Wolof, the local
language. This methodology was approved by the National Ethics Committee of Senegal,
which carries out audits regularly along with ad hoc committees of the Ministry of Health, the
Pasteur Institute (Dakar, Senegal) and the Institut de Recherche pour le Développement (Mar-
seille, France). Patients’ records and information were de-identified prior to analysis.
Subsets of these populations were investigated for variants in PKLR, using different size
exploratory and validation cohorts (see Results). Exons and exon/intron junctions of the PKLR
gene were sequenced using primer pairs adapted from [34] (S1 Table). Sequences were aligned
to the PKLR gene (chr1:155259084–155270792) from the hg19 (Feb 2009) human assembly
(UCSC) using BioEdit Sequence Alignment Editor [42]. Haploview software [43] was used to
identify haplotypes for each community using common dbSNPs (MAF10%). Using Custom
Taqman SNP primers and probes designed for rs147659527 (L272V) and R41Q, the presence
of these variants were analyzed within the Senegalese and Thai communities, respectively. In
addition, we examined the R41Q variant in 340 unrelated individuals from six Southeast Asian
populations (52 Mon, 62 Burmese, 65 Cambodian, 104 Thai, and 57 Lao).
Association studies and statistical analysis
The rs147659527 (L272V) genotypes were determined using custom Taqman SNP primers.
The R41Q genotypes were determined using a high-resolution melting test with forward
primer 5’-AAGGGCAGGTGACATGCAGT -3’ and reverse primer 5’-TGCTGCTGGAA
GAAGGCAGT-3’, and analyzed with a CFX96 Touch Real-Time PCR Detection System
(BIO-RAD). HRM genotypes were confirmed by PCR-RFLP, and by direct sequencing of PCR
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products. When possible, familial segregation of genotypes was verified using the Pedcheck
software [44]. In the Thai cohort (S2 Table), we tested association of the R41Q variant with 37
blood cell counts and associated haematological parameters, as well as with 9 malaria-related
phenotypes as described [6] (listed in S3 Table). All malaria-related phenotypes were analyzed
for R41Q genotypes and no associations were detected except for the two phenotypes, the Plas-
modium falciparum attacks and Plasmodium vivax attacks. There is no trait defining the
“severity” of malaria per se in this hypo-endemic area. Attacks are defined as measured fever
(axillary temperature> 37.5°C) or fever-related symptoms including headache, back pain,
chills, myalgia, nausea and vomiting, associated with a blood smear positive for blood-stage
trophozoite P. falciparum or P. vivax. The delay between two attacks with the same parasite is
at least 30 days. For the two attack phenotypes, a Generalized Linear Mixed Model was fitted
with the individual person as a factor in the random model. A Poisson error structure was
implemented, thus yielding a log-linear regression. “Explanatory factors” include year (1998–
2005), month, hamlet, and gender, with age factored into eight groups. The Pearson residual
variance, not explained by “environmental” factors, was generated for each attack, and the sum
of the residuals per person and for each parasite was used as the attack phenotype. R41Q het-
erozygotes were compared with R41 wild-type homozygotes for each trait using a parametric
ANOVA test, taking into account normal variables affecting these traits. For non-Gaussian dis-
tribution, the non-parametric Kruskal-Wallis equality-of-populations rank test with one
degree of freedom was also utilized. Analysis was completed first on non-stratified and then on
gender-stratified samples. For ANOVA, mean ± SEM and the number of individuals were
given for each group.
Preparation of wild-type and mutant PKLR constructs
Wild-type (WT) PKLR cDNA in a pET-21a vector was generously provided by Dr. G. Valentini
(University of Pavia, Italy). An NheI restriction site (5’-G^CTAGC), Kozak consensus
sequence (5’-CCACC) and an HA epitope tag (5’-TACCCATACGATGTTCCAGATTACGC
T) were added to the N-terminus, while a (His)6 tag (5’-ATGATGATGATGATGATG) was
added at the C terminus via PCR amplification using primer pairs (5'-GTG CTA GCC CAC
CAT GTA CCC ATA CGA TGT TCC AGA TTA CGC TTC GAT CCA GGA GAA CAT ATC
ATC C -3’ and 5'-TAA TGT TCT AGA TCA ATG ATG ATG ATG ATG ATG GGA TAT GC
T TAG CAC CCG CAT GA -3’). The WT construct was inserted into the pcDNA3 vector and
used as template for the introduction of mutations by site-directed mutagenesis (QuikChange
site-directed mutagenesis kit, Stratagene) using mutation primers (S4 Table). The veracity of
mutant variants was verified by DNA sequencing (S5 Table).
Protein Expression Studies
Twenty-four hours prior to transfection, 5 x 105 HEK293T cells/well were plated in complete
media [DMEM (Wisent Inc., St. Bruno, QC) + 10% FBS (Wisent, Inc.) + penicillin/streptomy-
cin (ThermoFisher Scientific, South Logan, Utah)] in 6-well tissue culture dishes. Recombinant
PKLR construct DNA was mixed with Opti-MEM (Life Technologies) and Lipofectamine 2000
(Invitrogen, Carlsbad, CA) prior to being added to cells supplemented with fresh DMEM +
10% FBS. Transiently transfected cells were harvested 18 hrs later. In some experiments, trans-
fected cells were plated in complete medium supplemented with 0.5mg/mL Geneticin (G418,
Gibco Life technologies, Grand Island, NY), and G418-resistant colonies were isolated 14 days
later. Transfected cells were washed in 1xPBS (HyClone, Logan, Utah), then sonicated in PBS
(6x15sec) on ice (Vibra-cell Sonicator, Sonics and Materials Inc., Newtown, CT). The total
protein concentration within the cell lysate was quantified using a Bradford assay (Bio-Rad
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Laboratories, USA), and equal amounts of protein lysate were separated on a 10% SDS-PAGE
gel, followed by immunoblotting against HA.11 Clone 16B12 purified monoclonal antibody
(mouse) (Covance Inc., Princeton, NJ) and β-actin antibody (mouse) (Covance Inc.) as a load-
ing control. The secondary antibody, ECLTM Anti-mouse IgG, Horseradish Peroxidase linked
whole Ab (from sheep) (GE Healthcare Ltd., Buckinghamshire, UK), was used in conjunction
with SuperSignal WestPico Chemiluminescent substrate (ThermoFisher Scientific) for protein
detection.
Protein Stability Assay
For protein stability assays, cells were incubated in methionine- and cysteine-free DMEM
media containing 10% dialyzed FBS, and 55 μCi of [35S] methionine-cysteine (Perkin-Elmer,
Boston, MA). Cells were then washed twice with PBS and incubated in chase medium (stan-
dard DMEM containing 10% FBS, 100 μg/ml methionine and 100 μg/ml cysteine) for up to 24
hours. For immunoprecipitation, equal amounts of cell lysates were incubated with the mouse
anti-HA antibody overnight at 4°C, followed by incubation with protein A/G-sepharose (GE
Healthcare, Piscataway, NJ) for 4 hrs. Beads were washed three times in RIPA buffer and pro-
teins were eluted with 50μl of 3X Laemmli sample buffer. The radiolabeled proteins were sepa-
rated by electrophoresis using 7.5% SDS polyacrylamide gels. The gels were then fixed,
impregnated with Amplify (GE Healthcare, Piscataway, NJ), dried and exposed to film. Densi-
tometric analysis was performed using NIH ImageJ software (NIH, Bethesda, MD).
Mice and parasite
CBA/Pkslc mice were provided by the Japan SLC Animal Facility (Mr. H. Asai) and subse-
quently maintained as a breeding colony at McGill University. CBA/CaHn-Btk/J mice were
purchased from Jackson Laboratories (Bar Harbor, ME, USA). All mice were kept under spe-
cific pathogen free conditions and handled according to the guidelines and regulations of the
Canadian Council on Animal Care. Mice experimentation protocol was approved by the
McGill Facility Animal Care Committee (P. Gros, Principal Investigator; protocol number:
5287), and include procedures to minimize distress and improve welfare. An LDH virus-free
isolate of Plasmodium chabaudi AS (D. Walliker; University of Edinburgh) was maintained by
weekly passage in A/J mice by intra-peritoneal infection with 106 parasitized erythrocytes
(pRBCs) [45]. For blood-stage infections, 8–12 weeks old mice were infected i.v. with 105
pRBCs suspended in pyrogen-free PBS; blood parasitemia was monitored daily (days 4–28) on
thin blood smears stained with Diff-Quik (Dade Behring). Mice infected with Plasmodium cha-
baudi were monitored twice daily for appearance of malaria symptoms at the peak of blood
stage replication. Animals showing lethargic behavior and/or ruffled fur appearance or signifi-
cant weight loss were sacrificed following anesthesia.
Results
PKLR genotypes in informative Senegalese and Thai populations
We investigated three populations living in areas of endemic malaria (Senegal; Thailand), and
in which several haematological and malarial phenotypes were followed longitudinally [6–8,
11, 39]. In these populations, we tested the hypothesis that coding or non-coding variants in
the PKLR gene may be associated with differential response to the malarial parasite, including
episodes and intensity of infections. As a first step, we sequenced exons and intron/exon junc-
tions of the PKLR gene in an exploratory cohort of 62 individuals from Senegal (35 from
Dielmo, 27 from Ndiop) and 6 individuals from the Thai-Myanmar border region.
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Nineteen single nucleotide polymorphisms (SNPs) were identified in the Senegalese com-
munities (Table 1), including several known dbSNPs (MAF>10%) as well as a number of rarer
variants. Of note, rs147659527 (c.853C>G) causes a conservative L272V substitution identified
in a single homozygous Ndiop individual (Table 1). Upon further investigation, this individual
did not display symptoms of PK-deficiency, suggesting that L272V does not affect PKLR pro-
tein activity and/or is phenotypically neutral. PKLR haplotypes were defined using eight SNPs
with MAF>10% (rs8177964, rs3020781, rs2071053, rs4620533, rs1052176, rs1052177,
rs932972, and rs8847). The Dielmo and Ndiop communities displayed five haplotypes each,
three of which were shared between them, with the remaining less frequent haplotypes being
unique to each community (Fig 1).
In the six Thai individuals sequenced, several common dbSNPs were present in addition to
a novel non-synonymous mutation (c.161A>G) detected in a single individual (Table 1),
resulting in a coding change from an arginine at residue 41 to glutamine (R41Q) (Fig 2). R41 is
highly conserved across species and the arginine to glutamine substitution is not conservative
and results in the loss of the positive side chain of wild-type R41. Sequencing an expanded
cohort of 96 Thai individuals identified nine samples positive for R41Q (all heterozygotes),
Table 1. Single nucleotide polymorphisms and alternative allele frequencies within the sequenced population.
Senegal Thailand
SNP Position Coding Ref Alt Dielmo % (Total) Ndiop % (Total) Combined % (Total) dbSNP build 138 (%)
rs187698692 155270961 C T 1.43 (35) 0.05
rs149505733 155270855 G A 1.58 (95) 0.14
SNP1 155270758 A G 1.43 (35)
R41Q 155270050 R41Q G A 4.90 (102)
rs8177962 155269991 L61L C T 1.43 (35) 0.53
rs8177963 155269830 T A 10.00 (35) 3.85 (26) 1.28
rs8177964** 155269780 C T 14.29 (35) 7.69 (26) 3.12
rs3020781** 155269776 C T 54.29 (35) 42.31 (26) 28.92 (102) 49.30
K105K 155265516 K105K G A 1.85 (27)
rs2071053** 155265177 T C 47.14 (35) 59.26 (27) 72.11 (95) 45.75
SNP2 155264607 C G 1.47 (34)
rs200695047 155264433 V269F G T 4.08 (98) 0.09
rs147659527 155264424 L272V C G 3.85 (26) 0.16
rs8177979 155263430 C T 4.29 (35) 3.70 (27) 1.70
SNP3 155263186 T C 1.43 (35)
rs61208773 155263166 C A 1.85 (27) 1.42
rs4620533** 155262613 G C 35.71 (35) 53.70 (27) 71.67 (90) 49.47
rs139885057 155262334 T C 4.29 (35) 3.70 (27) 1.93
rs3762272** 155261777 G A 66.84 (98) 26.62
rs1052176** 155260383 R569R C A 31.43 (35) 50.00 (27) 71.58 (95) 41.66
rs1052177** 155260350 T C 31.43 (35) 50.00 (27) 71.58 (95) 47.62
rs932972** 155260096 C T 31.43 (35) 50.00 (27) 71.58 (95) 48.61
rs8847** 155259323 G A 30.88 (34) 50.00 (26) 71.50 (100) 46.45
All coding and non-coding PKLR variants identified within the Senegalese (total n = 62) and Thai (total n = 102; six from the exploratory cohort plus an
additional 96 in the expanded Thai cohort) populations, with the alternative allele frequency (%) within the sequenced population. The total numbers of
successfully sequenced samples are noted in parenthesis. Alternative allele frequencies registered within the dbSNP build 138 database (genome.ucsc.
edu) are included for comparison. SNPs used to define haplotypes are marked with a “**”.
doi:10.1371/journal.pone.0144555.t001
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establishing an allele frequency of ~5% for this coding variant in the Thai population. Eleven
additional variants with minor allele frequency> 1% were detected in the Thai cohort, includ-
ing rs200695047 (c.844G>T) which codes for a valine to phenylalanine substitution at amino
acid 269 (V269F). This mutation was identified in one homozygous and six heterozygous sam-
ples. V269 is not conserved throughout evolution (Fig 2) and the V269F homozygote did not
display symptoms of PK-deficiency, suggesting that V269F does not affect PKLR protein activ-
ity. Haplotype analysis with informative SNPs (rs3020781, rs2071053, rs4620533, rs3762272,
rs1052176, rs1052177, rs932972, rs8847) revealed 3 haplotypes in the Thai sample, with the
most common haplotype (68.9%) being unique to the Thai community, and the two less fre-
quent haplotypes being shared with the Senegalese samples (Fig 1). Interestingly, the R41Q var-
iant was detected on the Thai-specific haplotype (Haplotype 1, Fig 1) suggesting that this
mutation may be population-specific, having arisen on a Southeast Asian genetic background.
Fig 1. PKLR gene variants discovered in both the Senegalese and Thai community. (a) Location of coding and non-coding variants within the PKLR
gene. Encoded on chromosome 1q22 (155259084–155270792 base pairs), the erythrocyte isoform, transcribed from a tissue specific promoter has 11
exons (blocks). (b) Haplotypes and haplotype frequencies for sequenced population. Determined using the Haploview software, haplotypes were defined by
the SNPs with a MAF 10% that defined the Senegalese and Thai populations. Seven of the SNPs were shared within the three study populations, while
rs4620533 was specific for the Senegalese populations and rs3762272 was found only within the Thai population. Haplotype frequency distribution were
calculated for the complete data set (ALL), or subdivided on country (Thailand, THA; Senegal, SEN) or village (Dielmo, DLM; Ndiop, NDP).
doi:10.1371/journal.pone.0144555.g001
Modulation of Malaria Phenotypes by Pyruvate Kinase
PLOS ONE | DOI:10.1371/journal.pone.0144555 December 14, 2015 7 / 18
Population genetic analysis of the R41Q and L272V variants in PKLR
Further characterization of possible associations between the L272V and R41Q variants and
malarial phenotypes was undertaken, as these variants affect residues that are highly conserved
in the PKLR protein family and may affect PKLR function. The L272V mutation
(rs147659527) was identified in one homozygous individual from the Senegalese community
of Ndiop. Further genotyping of the Ndiop community revealed that L272V was present in a
single family, where the grandmother was homozygous, and three of her children and a grand-
child were heterozygous. This family is one of 12 Fulani families in the Ndiop community (85
individuals), an ethnic group distributed throughout Western and Central Africa [18, 47, 48].
Additional sequencing of the PKLR gene in 149 unrelated individuals of Mossi (n = 89) and
Fulani (n = 60) ethnicity from Burkina Faso identified three L272V heterozygotes in Mossi
individuals. Hence, the L272V variant appears to be a rare variant (0.2%-1.5%; dbSNP build
138) distributed in different African populations. The relatively rarity of this variant in the
African populations available was too low to examine possible association with haematological
or malarial phenotypes.
Amongst the 102 Thai samples sequenced, we detected ten R41Q heterozygotes. Genotyp-
ing this mutation in the entire study population consisting of 871 samples from 181 families,
and from 46 unrelated individuals identified one homozygote individual and 81 heterozygotes
(71 of Karen origin), representing a mutant allele frequency of approximately 4.7% in this pop-
ulation. The R41Q genotypes exist in Hardy-Weinberg equilibrium (HWE) in this Thai sample
set. The homozygous R41Q mutant individual did not exhibit extreme blood phenotypes,
although its erythrocyte and reticulocyte counts were both low (falling within the lowest 10th
and 25th percentile; data not shown). The predicted allele frequency of 5% may provide suffi-
cient statistical power for association studies.
Fig 2. PKLR coding variants identified in the test populations. (a) Schematic representation of the PKLR protein, location of catalytically active residues
(phosphoenolpyruvate, PEP, binding residues; R116, G338, D339, and T371) and allosteric regulation site (fructose-1,6-bisphosphate, FBP, binding site;
loops 475–490 and 557–566, and residue R532) within structural domains [34, 46], and location of non-synonymous mutations identified from sequencing
(R41Q, V269F and L272V). (b) Subset of multiple species protein alignment by Clustal Omega (www.ebi.ac.uk) where “*” = single, fully conserved residue;
“:” = strongly similar properties
doi:10.1371/journal.pone.0144555.g002
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Genotyping for the R41Q mutation in an additional 340 unrelated Southeast Asian control
samples, detected 13 R41Q heterozygotes, consisting of 2 Cambodians, 2 Laos, 2 Thais, 4
Myanmarese, and 3 Mons. The R41Q genotypes exist in HWE in this sample set with the allele
frequency in each population, 1.5% in Cambodians, 1.8% in Laos, 1% in Thais (mixed ethnic-
ity), 3.2% in Myanmarese, and 2.9% in Mon. It is interesting to note that the frequency of the
R41Q allele is low in the general Thai population (~1%), while it is higher in the Thais of Karen
ethnicity (~5%) who generally live in malaria-endemic areas. Similarly, the frequency of the
R41Q allele is higher in the Myanmarese population (~3.2%), where a large population of eth-
nic Karen reside [49].
Association studies
Among the 871 Thai individuals genotyped for R41Q, one individual was homozygous for the
mutation, 81 were heterozygous and 789 had the wild-type genotype. Associations between
R41Q heterozygosity and various blood andmalarial parameters listed in S3 Table and previously
described [6], were examined. No association was detected between R41Q status and erythrocyte
count, hematocrit, or reticulocyte levels and any other phenotypes except two. Indeed, a signifi-
cant statistical association was noted between R41Q heterozygosity and a reduced frequency of
Plasmodium falciparum attacks (mean frequency of heterozygotes (mHe) = -0.23 ± 0.09 (n = 65)
and mean frequency of homozygous wild-type (mHo) = 0.01 ± 0.03 (n = 649); ANOVA
p = 0.0097, Kruskal-Wallis (KW) p = 0.0022), with this association being significant only in
females (mHe = -0.30 ± 0.11 (n = 34) and mHo = 0.01 ± 0.05 (n = 346); ANOVA p = 0.0260, KW
p = 0.0053 versus mHe = -0.16 ± 0.13 (n = 31) and mHo = 0.02 ± 0.05 (n = 303) ANOVA p = 0.17,
KW p = 0.1436 for males) (Fig 3A). Additionally, we determined that individuals heterozygous
for R41Q are significantly more susceptible to Plasmodium vivax attacks than Plasmodium falcip-
arum attacks (mHe = 0.49 ± 0.18 (n = 65) and mHo = -0.07 ± 0.04 (n = 649); ANOVA p = 1.32
10−4) again limited to females (mHe = 0.84 ± 0.28 (n = 34) and mHo = -0.07 ± 0.05 (n = 346),
ANOVA p = 7.1 10−5) and not males (mHe = 0.10 ± 0.15 (n = 31) and mHo = -0.08 ± 0.06
(n = 303), ANOVA p = 0.31). This result strongly suggests that females and not males are differ-
ently susceptible to Plasmodium falciparum attacks and to Plasmodium vivax attacks depending
on R41Q heterozygosity. Gender-specific effects for blood-stage malaria phenotypes have been
previously reported in humans [11], and mice [45]. These findings suggest that heterozygosity
for R41Qmay have an impact on host susceptibility to infection with malarial parasites in
endemic areas of disease.
Heterozygosity for Pklr in mice protects against peak parasitemia
In humans and mice, pyruvate kinase deficiency is inherited in a strictly recessive fashion, with
heterozygotes displaying no clinical symptoms, and displaying normal haematological profiles.
Nevertheless, we have previously shown that P. falciparum-parasitized erythrocytes from sub-
jects heterozygous for loss of function at PKLR are phagocytized more avidly than similarly
infected wild-type erythrocytes [30, 33]. Hence, we tested the effect of heterozygosity for the
known loss of function mutation at murine Pklr (G338D) [50], on haematological replication
of the malarial parasite in a mouse model of infection with P. chabaudi. For this, wild-type con-
trols (CBA/CaHn-Btkxid/J), pyruvate kinase deficient mutants (CBA/Pkslc) homozygous for a
loss of function allele at Pklr (G338D), as well as F1 heterozygotes (G338D/+) were infected
with P. chabaudi AS and blood parasitemia was followed over time (Fig 3C). We observed that
male mice of all genotypes were more susceptible than female mice, in agreement with a previ-
ous report [45]. However, we noted that at the peak of infection (peak parasitemia), G338D/+
heterozygotes displayed lower peak parasitemia values than their wild-type counterparts
Modulation of Malaria Phenotypes by Pyruvate Kinase
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Fig 3. Effect of human andmouse PKLR variants onmalaria phenotypes. (a) Association of the R41Qmutation and Plasmodium falciparum attacks in
the genotyped Thai population. Residual Plasmodium falciparum attacks for heterozygous (R41Q) and homozygous wild-type (R41R) individuals. Both
parametric and non-parametric tests indicate statistically significant decrease in attacks for heterozygous females only (ANOVA p = 0.0260 Kruskal-Wallis
(KW) p = 0.0053). (b) Residual Plasmodium vivax attacks for heterozygous (R41Q) and homozygous wild-type (R41R) individuals. A statistically significant
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(CBA/J), and this for both male (two-tailed unpaired t-test p = 0.0378) and female mice
(p = 0.0264) (Fig 3D). In males, this significant difference in blood parasitemia between wild-
type and G338/+ heterozygotes extended from day 7–9 post-infection (p = 0.0188; p = 0.0290).
This suggests that heterozygosity for mutant Pklr variant in mice improves response to infec-
tion with the malarial parasite.
R41Q recombinant protein exhibits modest effect on half-life
Overexpression of the R41Q variant in transiently transfected HEK293T cells, followed by
semi-quantitative measurement of pyruvate kinase activity (PK-LDH assay) failed to detect a
major effect of the R41Q mutation on basal enzymatic activity in such over-expressing cells
(data not shown). We also examined the effect of the R41Q mutation on stability of the tran-
siently transfected [35S]-methionine labelled protein in pulse-chase studies (Fig 4). In three
independent experiments, we observed a shorter half-life for R41Q compared to WT protein
expressed in transfected cells: The effect was modest but reproducible, suggesting that R41Q
may affect protein stability in these cells.
Discussion
Malaria kills one child every minute in Sub-Saharan Africa [51, 52]. Over time, selective pres-
sure from such a lethal infection has resulted in the genetic retention in malaria endemic areas
of certain allelic variants that confer partial protection against disease. The erythrocyte is the
major replication niche of the Plasmodium parasite, and variants in certain erythrocyte pro-
teins have been found enriched in malaria-endemic areas. Although homozygosity for such
variants causes disease on their own (sickle cell anemia, thalassemias, G6PD deficiency), het-
erozygosity confers various degrees of protection against malaria [1–3, 53, 54]. We have previ-
ously shown that homozygosity for loss of function mutations within the erythrocyte pyruvate
kinase gene (Pklr) in mice reduces the severity of infection with the blood stage parasite P. cha-
baudi AS [31, 32]. Likewise, in human erythrocytes infected ex vivo with P. falciparum, homo-
zygosity for PK-deficiency alleles causes a reduction in parasite replication, while parasitized
erythrocytes from heterozygotes are phagocytized more avidly than those from normal individ-
uals [30, 33]. Using comparative analyses of archival populations contained in the CEPH
Human Diversity panel from current and ancestral areas of malaria, we detected rich genetic
diversity in the PKLR gene, including the presence of rare, potential loss-of-function protein
variants. Neutrality testing of PKLR haplotypes and variants suggested positive selection of the
gene in the sub-Saharan African and Pakistani populations, possibly by the malarial parasite
[34]. This hypothesis remained to be formally tested, and was the major aim of the current
study.
Herein, we probed for the possible association between rare or common variants at the
sequenced PKLR gene, and haematological and malaria-associated phenotypes in three popula-
tions from Thailand and Senegal, living in areas of seasonal or year-long exposure to the malar-
ial parasite. These populations were studied longitudinally for multiple phenotypes, including
but not limited to frequency and intensity of infection by the malarial parasites, thereby provid-
ing added power to detect genetic effects of the host in response to the parasite. The Thai
increase in attacks was noted in heterozygous females though only for the parametric test (ANOVA p = 0.0007), not the non-parametric test (KW p = 0.1789).
(c) Time course of P. chabaudi chabaudi AS infection in PK-sufficient (CBA/CaHn-Btkxid/J, circles), PK-deficient (CBA/Pkslc, triangles) and F1 generation
mice (squares). (d) Peak parasitemia (8dpi). Results are separated based on gender. Statistical significance was determined via unpaired, two-tailed t-tests,
calculated by GraphPad (Prism) where “*” represents p<0.05. Statistically significant differences between PK-sufficient and F1 heterozygotes was noted for
both genders (females: p = 0.0264, males: p = 0.0378).
doi:10.1371/journal.pone.0144555.g003
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population has been used in the past to document the effect of G6PD deficiency (Mahidol
allele) on differential susceptibility to infection with P. falciparum and P. vivax [11].
Sequencing the PKLR gene in subsets of Senegalese and Thai individuals identified a num-
ber of common variants (SNPs), nine of which were used to define PKLR haplotypes in these
populations. Eight PKLR haplotypes were detected, two of which were common and represent-
ing approximately 86% of the Senegalese and 31% of the Thai populations. These common
haplotypes are also present in various North, South, and Sub-Saharan African, Pakistani,
Southeast Asian and European populations [34]. Haplotype analysis at PKLR further detected
population substructure in the two Senegalese populations. The Dielmo community is com-
posed primarily of the Serere and Mandinka ethnic groups [7], while the Ndiop community is
comprised predominantly of Wolof and Fulani ethnicities [7]: unique PKLR haplotypes were
detected in these populations. Of particular interest is the Thai-specific haplotype 1 (Fig 1)
onto which the R41Q mutation appeared to have emerged. This strongly suggests that the
R41Q variant is population specific. We also detected the R41Q variant in Cambodian, Lao,
Myanmarese, and Mon populations from other malaria-endemic areas. Although malaria-
associated phenotypes are not available for these populations, presence of the R41Q mutation
suggests that the variant occurred on an ancient South-Asian haplotype which is shared
amongst populations of Thailand, Laos, and Cambodia.
Fig 4. Effect of R41Q on PKLR protein stability. (a) Transiently transfected HEK293T cells expressing
either the wild-type (WT) or the R41Qmutant PKLR proteins were metabolically labelled with [35S]-
methionine followed by chase in label-free media for the indicated time period (in hours). Cell lysates were
prepared and PKLR was immunoprecipitated, followed by gel electrophoresis. (b) The radiolabelled PKLR
species were quantitated using ImageJ software, and averages from 2–3 independent experiments were
calculated as a fraction of the maximum labelling observed at 0 hr.
doi:10.1371/journal.pone.0144555.g004
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Sequencing also identified three coding variants in the PKLR protein; these variants affected
residues that were either highly conserved (R41, L272), or coded for a very significant change
in amino acid property (V269F), both of which possibly result in altered protein function. The
L272V and V269F variants were present at very low frequency in the two populations, and
association with haematological and malaria traits could not be conducted with sufficient sta-
tistical power. Genotyping revealed that the R41Q mutation was present with a minor allele
frequency of approximately 4.5% within the Thai cohort. We noted a statistically significant
association between R41Q heterozygosity and a reduced frequency of Plasmodium falciparum
attacks, with this association being significant only in females. Additionally, there appears to be
a tendency for R41Q heterozygotes to be more susceptible to infection with Plasmodium vivax,
although this was only significant in parametric, rather than non-parametric tests, and again
limited to females (Fig 3A and 3B). Although these findings require replication in additional
cohorts of individuals with informative R41Q genotypes and from malaria-endemic areas, the
current results suggest a possible association of the R41Q variant with reduced susceptibility to
P. falciparum infection. The increased susceptibility to P. vivax infection noted in some R41Q
heterozygotes and concomitant to reduced susceptibility to P. falciparummay reflect immuno-
logical cross-reactivity and immune protection in regions of mixed infections [55]. On the
other hand, such genetically influenced differential susceptibility to different malarial parasites
has been previously reported in the case of glucose-6-phosphate dehydrogenase deficiency.
Indeed, it was demonstrated that the G6PDMahidol (487A) variant reduces infection with P.
vivax, but not with P. falciparum in a population from South Asia, suggesting that Plasmodium
vivax has been a driving force behind the strong selective advantage conferred by this mutation
[11].
Pyruvate kinase is composed of an amino terminal (N) domain with a helix-turn-helix
motif, followed by a bi-partite A domain (A1, A2) that contains residues implicated in binding
the phosphoenolpyruvate (PEP) substrate, as well as a conserved B domain linker, followed by
the C-terminal domain that binds the allosteric regulator fructose-1,6-bisphosphate (FBP) (Fig
2). Structure function studies have shown that PKLR exists either in the active R-state or the
inactive T-state, and that the state of activation is regulated by intra- and inter-domain interac-
tions between the A and C domains of adjacent subunits as well as the A/B and A/C domains
within a subunit [26, 56, 57]. The R41Q mutation is located within the N-terminal domain of
PKLR, and the arginine residue is highly conserved in mammals. While overexpression of the
R41Q variant in transfected cells failed to identify a significant effect of the mutation on enzy-
matic activity, we noted a modest but reproducible effect of R41Q on protein half-life in pulse-
chase studies.
In addition to basal activity, there are number of structural and functional aspects of PKLR
that may be affected by R41Q. PKLR activity is regulated in part by phosphorylation of serine
43, which causes increased affinity for allosteric inhibitors ATP and alanine, and decreased
affinity for PEP and the allosteric activator FBP [58, 59]. Two mutations mapping to the N-ter-
minal domain of PKLR (near R41Q) have been functionally characterized. One mutation
(A36G) identified in a case of congenital nonspherocytic hemolytic anemia with PK-deficiency,
was shown to partially impair enzyme activity [60]. A possible gain-of-function variant (G37E)
was found associated with enzyme hyper-activity, increased ATP levels, and possibly linked to
altered phosphorylation of S43 [61, 62]. Additionally, the PK-R isoform undergoes post-trans-
lational proteolytic cleavage of the N-terminus during erythrocyte maturation, generating full
length and truncated proteins with different capacity for homo- and heterotetramerization [24,
26, 46, 57, 63]. Also, fructose-1,6-bisphosphate promotes tetramer formation, while ATP
causes tetramer disassociation (PK-R/L, M2) [64, 65]. Together, these findings suggest that the
N-terminal domain of PKLR that carries the R41Q variant plays a key role in enzyme function,
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regulation of activity and functional oligomerization. Finally, PKLR monomers can oligomer-
ize with monomers from the other isoform, PK-M2, leading to the formation of hybrids that
contain 1 to 3 subunits of either isoform [66–69]. PK-M2 is broadly expressed in most cells
lines used in transfection studies, including HEK-293 cells used herein, which further compli-
cates the functional study of PKLR variants expressed in these cells. Indeed, it is possible that
R41Q affects the ability of the PK-R enzyme to heterodimerize with background PK-M2 pro-
teins present in transfected cells, leading to PK multimers of unknown activity.
Finally, it has been observed that some disease-associated PKLRmutations do not affect
enzymatic activity of the purified protein. For example, the R510Q mutant in a patient with
nonspherocytic hemolytic anemia shows wild-type kinetic activity and regulatory properties
when expressed in bacteria [57]: However, R510Q exhibits significantly lower thermal stability
when compared to the wild-type control, suggesting that protein instability rather than reduced
enzymatic activity is responsible for PK-deficiency in R510Q patients [57]. Additional studies
will be required to characterize the molecular effect of the R41Q variant on PKLR structure
and function.
Although our study requires additional validation in other cohorts where longitudinal data
on haematological malaria phenotypes are available, results obtained so far strongly suggest
that allelic variants at PKLR modulate susceptibility to Plasmodium infection in humans, with
protective alleles possibly retained in populations living in areas of endemic malaria. The
cumulative data supporting this proposal include: a) the demonstration that homozygosity for
loss of function at Pklr cause complete protection against blood-stage malaria (P. chabaudi AS)
in mice [31, 32], with heterozygotes showing reduced levels of blood-stage parasitemia (Fig 3);
b) homozygosity and heterozygosity for human PK-deficiency associated loss of function
alleles at PKLR cause a reduction in parasite replication and increase phagocytosis of parasit-
ized erythrocytes in studies with primary erythrocytes infected ex vivo with P. falciparum [30];
c) the PKLR gene shows highest sequence diversity in regions where malaria is or has been
endemic, when compared to regions where it has not been prevalent [34]; d) a unique PKLR
variant (R41Q) with reduced protein stability has appeared on a common haplotype from
Southeast Asia and shows an association with reduced number of malaria attacks in females
from a large Thai cohort of Karen ethnicity from a malaria endemic area. Therefore, along with
haemoglobin, glucose-6-phosphate dehydrogenase, anion exchanger band 3, and several oth-
ers, PKLR would represent another example of an erythrocyte-specific protein in which hetero-
zygosity for partial or complete loss of function variants confer some degree of protection
against malaria.
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